Table 1 Anamnestic and survival data of patients receiving immunomodulating therapy (IMT). Unless otherwise indicated, continuous and count data are presented as the mean ± standard deviation and the number of observations, respectively.

Age (year)

49.00 ± 15.68

55.83 ± 9.61

53.96 ± 14.44

54.74 ± 13.72

52.02 ± 11.93

Sex (male : female)

7 : 14

5 : 9

2:3

1:4

0:4

Body-mass index (kg/m²)

22.21 ± 3.62

22.60 ± 4.61

23.80 ± 1.82

22.36 ± 6.64

22.76 ± 2.76

Primary tumor

 Completely / partially resected

19/0

7/0

1/0

1/1

1/0

 Inoperable or not operated

2

7

4

3

3

TNM⁴⁰

 T: 1/2/3/4/irresectable

2/2/8/7/2

0/3/2/2/7

0/1/0/0/4

1/0/0/0/4

0/0/0/1/3

 N: 0/1/2/irresectable

3/7/9/2

4/3/0/7

1/0/0/4

0/0/1/4

0/0/1/3

Metastasis: synchronous / metachronous

11/9

8/5

3/1

4/1

2/2

Location of metastases

 Liver

12

7

3

1

2

 Lung

8

4

1

1

2

 Distant lymph nodes

9

1

3

2

2

 Peritoneal

7

3

0

3

0

 Ovarium

3

1

0

1

0

 Locoregional

4

3

0

0

0

 Other (e.g., bone, brain)

0

2

1

3

0

Medical history prior cancer diagnosis

 Hypertension

4

3

2

0

0

 Diabetes mellitus

4

0

0

0

0

 Stroke / MI / other CV diseases ¹

0/3/3

0/0/2

0/0/3

0/0/0

0/0/0

 Thyroid disease

4

2

1

0

0

 Autoimmune disease

4

0

1

0

0

Time to first IMT (month)

23.08 ± 20.15

12.53 ± 14.07

19.69 ± 10.69

4.02 ± 3.56

13.03 ± 10.31

Median survival time since the

 Tumor diagnosis (month)

48.99

28.98

30.09

13.01

31.34

 1^st day of IMT (month)

20.01

17.91

11.53

9.00

21.82

 Last day of IMT (month)

15.41

9.31

10.51

1.15

5.73

Survival rate since 1^st IMT

 1-year (%)

57.1

64.3

40.0

20.0

75.0

 2-year (%)

41.9

21.4

20.0

0

25.0

 3-year (%)

27.9

0

0

0

0